MYNZ
Mainz Biomed BV
NASDAQ: MYNZ · HEALTHCARE · DIAGNOSTICS & RESEARCH
$0.34
+0.41% today
Updated 2026-06-03
Market cap
$7.90M
P/E ratio
—
P/S ratio
16.01x
EPS (TTM)
$-5.28
Dividend yield
—
52W range
$1 – $5
Volume
21.4M
WallStSmart proprietary scores
18
out of 100
Grade: F
Strong Sell
Investment rating
4.7
Growth
C4.0
Quality
C2.5
Profitability
F5.0
Valuation
C+6/9
Piotroski F-Score
Moderate
-14.0
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →199 stocks currently score above 75
Price targets
Analyst target
$14.00
+3994.76%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Altman Z -14.01 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-6.52M
- Revenue declining -0.45% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Revenue | $577348.00 | $529877.00 | $895479.00 | $893991.00 | $659940.00 |
| Net income | $-11.69M | $-26.45M | $-26.30M | $-21.65M | $-8.34M |
| EPS | — | — | — | — | $-5.28 |
| Free cash flow | $-3.24M | $-15.43M | $-23.84M | $-17.34M | $-6.52M |
| Profit margin | -2,024.79% | -4,992.24% | -2,936.50% | -2,421.80% | — |
Peer comparison
Smart narrative
Mainz Biomed BV trades at $0.34. Our Smart Value Score of 18/100 indicates the stock is weak. The company scores 6/9 on the Piotroski F-Score. With an Altman Z-Score of -14.01, it sits in the distress. TTM revenue stands at $659940.00.
Frequently asked questions
What is Mainz Biomed BV's stock price?
Mainz Biomed BV (MYNZ) trades at $0.34, on a P/S of 16.0x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Mainz Biomed BV overvalued?
Mainz Biomed BV carries a Smart Value Score of 18/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Mainz Biomed BV (MYNZ)?
The 12-month analyst consensus target is $14.00, about 3994.8% above the current $0.34. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Mainz Biomed BV's revenue?
Mainz Biomed BV's trailing twelve-month revenue is $659940.00. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Mainz Biomed BV's Altman Z-Score is -14.01, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDIAGNOSTICS & RESEARCH
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio16.01x
ROE-4.66%
Beta0.26
50D MA$1.55
200D MA$2.71
Shares out0.01B
Float0.00B
Short ratio—
Avg volume21.4M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—